Takashima, Naoki <br/><br/>
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.  [electronic resource] 

 -  Onkologie  2012 
 - 747-52 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1423-0240 
<br/><br/><label>Standard No.: </label>10.1159/000345039  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Comorbidity<br/>Dose-Response Relationship, Drug<br/>Drug Eruptions--epidemiology<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Japan--epidemiology<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Prevalence<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Quinazolines--therapeutic use<br/>Risk Assessment<br/>Risk Factors<br/>Survival Analysis<br/>Survival Rate<br/>Treatment Outcome